Table 2.
Data based on the questionnaires.
| No. | Response to questionnaire | Age (y) | Current status | DLQI | ||||
|---|---|---|---|---|---|---|---|---|
| At onset | At response | At complete remission | Current improvement | Current Treatment | Current status | QOL disability | ||
| 1 | (+) | 55 | 69 | Improve (mild symp.) | (−) | 2 | Mild dist. | |
| 2 | (+) | 17 | 42 | Improve (mild symp.) | (−) | 5 | Mild dist. | |
| 3 | (+) | 67 | 80 | Improve (mild symp.) | (−) | 7 | Moderate dist. | |
| 4 | (+) | 48 | 63 | Deteriorate | UN | 20 | Severe dist. | |
| 5 | (+) | 60 | 77 | 71 | Complete remission | (−) | 0 | No dist. |
| 6 | NA | 23 | NA | NA | NA | NA | NA | |
| 7 | NA | 21 | NA | NA | NA | NA | NA | |
| 8 | (+) | 57 | 64 | 59 | Complete remission | (−) | 0 | No dist. |
| 9 | (+) | 23 | 37 | Improve (moderate symp.) | Clemastine Fumarate, Fexofenadine (UAN) | 16 | Severe dist. | |
| 10 | NA | 36 | NA | NA | NA | NA | NA | |
| 11 | NA | 6 | NA | NA | NA | NA | NA | |
| 12 | NA | 56 | NA | NA | NA | NA | NA | |
| 13 | (+) | 33 | 40 | 35 | Complete remission | (−) | 0 | No dist. |
| 14 | (+) | 60 | 69 | Improve (moderate symp.) | Olopatadine | 3 | Mild dist. | |
| 15 | NA | 17 | NA | NA | NA | NA | NA | |
| 16 | (+) | 17 | 31 | Improve (moderate symp.) | Levocetirizine (UAN) | 4 | Mild dist. | |
| 17 | NA | 29 | NA | NA | NA | NA | NA | |
| 18 | (+) | 35 | 43 | Improve (mild symp.) | (−) | 3 | Mild dist. | |
| 19 | (+) | 17 | 22 | Improve (moderate symp.) | Olopatadine | 13 | Severe dist. | |
| 20 | (+) | 11 | 17 | Improve (mild symp.) | (−) | 11 | Severe dist. | |
| 21 | NA | 23 | NA | NA | NA | NA | NA | |
| 22 | (+) | 17 | 21 | Improve (mild symp.) | (−) | 10 | Moderate dist. | |
| 23 | (+) | 67 | 69 | 68 | Complete remission | (−) | 0 | No dist. |
| 24 | (+) | 3 | 6 | Improve (moderate symp.) | Epinastine | 7 | Moderate dist. | |
| 25 | (+) | 51 | 53 | Improve (moderate symp.) | Levocetirizine, Lafutidine, Montelukast, hardening | 7 | Moderate dist. | |
| 26 | NA | 10 | NA | NA | NA | NA | NA | |
| 27 | (+) | 18 | 23 | Deteriorate | Fexofenadine (UAN) | 13 | Severe dist. | |
| 28 | (+) | 50 | 51 | Improve (moderate symp.) | Fexofenadine, hardening | 17 | Severe dist. | |
| 29 | (+) | 46 | 49 | Improve (moderate symp.) | Loratadine, Lafutidine | 10 | Moderate dist. | |
Y, year; DLQI, Dermatology Life Quality Index; CR, complete remission; UAN, use as needed; ND, not done; UN, unknown; NA, no answer; symp, symptom; dist., disturbance. The patients who did not answer to the questionnaires were described as gray rows. The patients’ number is coincident with Table 1. The same number expresses the same patient.